There are currently five approved ergotamine-containing drugs: Migergot suppositories (marketed by G & W Laboratories Inc.), ergotamine tartrate
and caffeine tablets (marketed by West-Ward Pharmaceutical Corporation and Mikart), Cafergot tablets (marketed by Sandoz), and Ergo-mar sublingual tablets (marketed by Rosedale Therapeutics).
NSAIDs, especially naproxen sodium, are considered an effective first choice of medication for menstrual migraine and may be administered both abortively and prophylactically for 1-2 days before the onset of migraines.[24,44] A double-blind study that compared the efficacy as well as safety of naproxen sodium and ergotamine tartrate
in a sample of 79 participants with classical or common migraine found that naproxen sodium was as safe as ergotamine tartrate
and somewhat more effective in acute migraine attacks. Adverse effects of NSAIDs consist of gastrointestinal irritation and chronic renal dysfunction.
Lysergol, lysergic acid, ergonovine, ergonovine maleate, ergovaline, ergotamine tartrate
, ergocryptine, and 2-bromo-ergocryptine were tested for cross reaction in a competitive ELISA assay.
Ergotamine -- Ergotamine tartrate
has been in use since 1928 (similar formulas are Cafergot, Ergomar, Ergostat Gynergen).